Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberico L Catapano

Showing results (1-10 of 388) with videos related to

Pageof 39
Sort By:
Atherosclerosis. Supplements|January 4, 2011
Pitavastatin - pharmacological profile from early phase studiesAlberico L Catapano
Current Medical Research and Opinion|February 6, 2009
Perspectives on low-density lipoprotein cholesterol goal achievementAlberico L Catapano
Atherosclerosis. Supplements|September 27, 2014
New strategies for the management of patients with homozygous familial hypercholesterolaemiaAlberico L Catapano
Atherosclerosis. Supplements|September 27, 2014
Management of homozygous familial hypercholesterolaemia--unmet needs, updated recommendations, and clinical experience with the MTP inhibitor, lomitapide. Concluding commentsAlberico L Catapano
Atherosclerosis. Supplements|February 10, 2015
New insights on ezetimibe. IntroductionAlberico L Catapano
Vascular Pharmacology|September 16, 2023
Emerging therapies in dyslipidaemiasAlberico L Catapano
Fundamental & Clinical Pharmacology|November 16, 2007
The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balanceAlberico L Catapano
Current Vascular Pharmacology|October 26, 2011
Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatinAlberico L Catapano
Nature Reviews. Cardiology|January 17, 2018
Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targetsAlberico L Catapano
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 24, 2017
Residual cardiovascular riskRoberto Ferrari, Alberico L Catapano
Pageof 39

Showing results (1-10 of 388) with videos related to

Sort By:
Pageof 39
Atherosclerosis. Supplements|January 4, 2011
Pitavastatin - pharmacological profile from early phase studiesAlberico L Catapano
Current Medical Research and Opinion|February 6, 2009
Perspectives on low-density lipoprotein cholesterol goal achievementAlberico L Catapano
Atherosclerosis. Supplements|September 27, 2014
New strategies for the management of patients with homozygous familial hypercholesterolaemiaAlberico L Catapano
Atherosclerosis. Supplements|September 27, 2014
Management of homozygous familial hypercholesterolaemia--unmet needs, updated recommendations, and clinical experience with the MTP inhibitor, lomitapide. Concluding commentsAlberico L Catapano
Atherosclerosis. Supplements|February 10, 2015
New insights on ezetimibe. IntroductionAlberico L Catapano
Vascular Pharmacology|September 16, 2023
Emerging therapies in dyslipidaemiasAlberico L Catapano
Fundamental & Clinical Pharmacology|November 16, 2007
The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balanceAlberico L Catapano
Current Vascular Pharmacology|October 26, 2011
Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatinAlberico L Catapano
Nature Reviews. Cardiology|January 17, 2018
Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targetsAlberico L Catapano
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 24, 2017
Residual cardiovascular riskRoberto Ferrari, Alberico L Catapano
Pageof 39